Judge Dismisses Amgen's Biosimilar Patent Dance Enforcement Lawsuit

A New Jersey District Court judge dismissed Amgen's court case challenging Sandoz's decision to cut short the patent dance process for its biosimilar of Amgen's Neulasta, leaving both parties waiting to see if the Supreme Court will take up their separate case that touches on whether a biosimilar applicant must provide the reference product sponsor their application and manufacturing information. The District Court opinion, dated July 22, stated that because both parties had agreed to end the patent dance process,...